Stocks with Buy Rank and Strong Income Characteristics - Primo Brands Corporation (PRMB): The Zacks Consensus Estimate for current year earnings has increased by 3.1% over the last 60 days The company has a dividend yield of 1.2%, significantly higher than the industry average of 0.0% [1] - Fresenius Medical Care AG (FMS): The Zacks Consensus Estimate for current year earnings has increased by 1.3% over the last 60 days The company has a dividend yield of 2.0%, compared to the industry average of 0.0% [2] - RB Global, Inc. (RBA): The Zacks Consensus Estimate for current year earnings has increased by 3.8% over the last 60 days The company has a dividend yield of 1.3%, higher than the industry average of 0.0% [2][3]

Group 1 - Payoneer Global Inc. (PAYO) has a Zacks Rank 1 with a 40% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [1] - Payoneer Global's shares increased by 33.3% over the last three months, outperforming the S&P 500's 5.0% gain [1] - TDK Corporation (TTDKY) also holds a Zacks Rank 1, with a 77.8% rise in the Zacks Consensus Estimate for its current year earnings over the last 60 days [2] - TDK Corporation's shares rose by 5.7% in the last month, compared to the S&P 500's 0.4% increase [2] - Fresenius Medical Care AG (FMS) has a Zacks Rank 1, with a 1.3% increase in the Zacks Consensus Estimate for its current year earnings over the last 60 days [3] - Fresenius Medical Care's shares gained 7.4% over the last three months, surpassing the S&P 500's 4.7% increase [3] Group 2 - Payoneer Global has a Momentum Score of B, indicating strong momentum characteristics [1] - TDK Corporation also possesses a Momentum Score of B, reflecting its positive performance [2] - Fresenius Medical Care has a Momentum Score of A, suggesting even stronger momentum characteristics compared to the others [3]

Core Viewpoint - Fresenius Medical Care will rejoin the DAX 40, the top tier of the German Stock Index, effective December 27, 2024, highlighting the company's recovery and strategic execution [5][7]. Company Overview - Fresenius Medical Care is the leading global provider of products and services for individuals with kidney diseases, serving approximately 4.1 million patients worldwide who regularly undergo dialysis treatment [6]. - The company operates a network of 3,732 dialysis clinics, providing treatments for around 308,000 patients globally [6]. - Fresenius Medical Care is also a major supplier of dialysis products, including dialysis machines and dialyzers [6]. Historical Context - The company was previously a member of the DAX since September 1999 but has been listed in the Mid-Cap DAX (MDAX) since March 2023, which tracks the 50 largest companies below the DAX 40 [7].

Core Insights - The article emphasizes the importance of earnings estimates and revisions in identifying strong stocks, while also acknowledging that investors have their own strategies [1] - Value investing is highlighted as a popular strategy that focuses on identifying undervalued companies through traditional valuation metrics [2] - Zacks has developed a Style Scores system to identify stocks with specific traits, particularly for value investors seeking high grades in the Value category [3] Company Analysis: Fresenius Medical Care AG & Co. (FMS) - Fresenius Medical Care AG & Co. currently holds a Zacks Rank of 2 (Buy) and has a Value grade of A, indicating strong potential for value investors [4] - The stock's Forward P/E ratio is 11.85, significantly lower than the industry average of 32.83, suggesting it may be undervalued [4] - Over the past year, FMS's Forward P/E has fluctuated between a high of 16.85 and a low of 10.51, with a median of 11.95, reinforcing the notion of its current undervaluation [4][5] - The combination of a strong earnings outlook and favorable valuation metrics positions FMS as an impressive value stock at this time [5]

Core Insights - Fresenius Medical Care AG & Co. reported third-quarter 2024 adjusted earnings per share (EPS) of 45 cents, exceeding the Zacks Consensus Estimate by 7.1% and reflecting a year-over-year improvement of 45.2% [1] - The company's revenues for the quarter were $5.23 billion (EUR 4,760 million), missing the Zacks Consensus Estimate by 2.4% and showing a decline of 3.6% year over year [2] Revenue Detail - Revenues were negatively impacted by divestitures, which reduced growth by 230 basis points [2] - Organic revenue growth was reported at 1.9% despite the overall decline [2] Segmental Details - Fresenius Medical has adopted a new operating model, reporting under two segments: Care Delivery and Care Enablement [3] - Care Delivery segment revenues decreased by 5.1% year over year but showed a 1% organic growth [3] U.S. Market Performance - U.S. revenues declined by 1.3% but gained 0.4% on an organic basis, remaining flat year over year at constant currency [4] - The U.S. same-market treatment growth improved to positive growth of 0.2% after adjusting for less profitable contracts [5] International Sales - International sales saw a significant decline of 21.6% but achieved 4.4% organic growth, supported by higher reimbursement rates [6] Margin Analysis - Operating income rose by 42.7% year over year, with an operating margin of 9.7%, up 310 basis points from the previous year [7] 2024 Guidance - The company maintained its revenue growth outlook for 2024 at a low-to-mid single-digit percentage rate, while revising operating income growth expectations to 16-18% [7] Operational Improvements - The newly implemented operating model has led to operational improvements, with the company generating EUR 64 million in savings through its FME25 transformation program [9][10] - The portfolio optimization plan is expected to negatively impact operating income by around EUR 250 million for the full year 2024 [10] Strategic Focus - Continued divestment of noncore and dilutive assets is seen as a positive move to focus on core categories and enhance cash resources [11]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.W ...

Organic revenue growth of +2% supported by Care Enablement and Care Delivery Underlying U.S. dialysis treatment volume growth turns positive Exceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3 Both segments further increased operating income1 and operating income margin1 Net financial leverage ratio further improved to 2.8x FY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNe ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their own strategies, so we are constantly looking at the latest trends in value, growth, and momentum to find strong companies for our readers.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use fundamental analysis and traditional val ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor. Zacks Premium also includes the Zacks Style Scores. What are the Zacks Style Scores? The Zacks Style ...

Fresenius Medical Care (FMS) is one of the largest integrated providers of products and services for individuals undergoing dialysis following chronic kidney failure. Through its network of more than 3,600 clinics across the world, the company offers dialysis services and products in more than 120 countries and employs over 109,000 staff in more than 50 countries. Fresenius Medical reports through two segments — Care Delivery and Care Enablement. The Care Delivery segment consists of the company's Dialysis ...